The EMPA-KIDNEY, Collaborative G, Herrington WG, Staplin N, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Judge P, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu W, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Massey D, Eilbracht J, Brueckmann M, Landray MJ, Baigent C, Haynes R
[PMID: 9691735] PubMed record related to this compound for laboratory literature review
In 2023 the FDA placed CJC-1295 in "Category 2" of its interim 503A bulks list, meaning it identified significant safety concerns and did not permit its use in traditional pharmacy compounding
Its still, on the other hand, potent enough to have gastrointestinal and systemic effects
The Damages Available To Victims GLP-1 plaintiffs may be entitled to recover for: Medical bills (past and future) Lost wages and diminished earning capacity Pain and suffering Loss of enjoyment of life Permanent disability Emotional distress In cases of egregious conduct, punitive damages We take time to understand each clients story, ensuring your claim fully reflects the ways this drug has changed your life